List of Excipients in Branded Drug CLOBETASOL PROPIONATE (EMMOLIENT)

Generic Drugs Containing CLOBETASOL PROPIONATE (EMMOLIENT)

Company	Ingredient	NDC	Excipient
ANI Pharmaceuticals Inc	clobetasol propionate	62559-980	ANHYDROUS TRISODIUM CITRATE
ANI Pharmaceuticals Inc	clobetasol propionate	62559-980	CETETH-20
ANI Pharmaceuticals Inc	clobetasol propionate	62559-980	CETOSTEARYL ALCOHOL
ANI Pharmaceuticals Inc	clobetasol propionate	62559-980	CITRIC ACID MONOHYDRATE
ANI Pharmaceuticals Inc	clobetasol propionate	62559-980	DIMETHICONE
ANI Pharmaceuticals Inc	clobetasol propionate	62559-980	ISOPROPYL MYRISTATE
ANI Pharmaceuticals Inc	clobetasol propionate	62559-980	METHYLPARABEN

What are the Most Frequently-Used Excipients in CLOBETASOL PROPIONATE (EMMOLIENT)?

# Of NDCs	Excipient
2	ANHYDROUS TRISODIUM CITRATE
2	CETETH-20
2	CETOSTEARYL ALCOHOL
2	CITRIC ACID MONOHYDRATE
2	DIMETHICONE
2	ISOPROPYL MYRISTATE
2	METHYLPARABEN

Clobetasol Propionate Emollient Excipient Strategy and Commercial Opportunities

Last updated: September 3, 2026

Clobetasol propionate emollient products compete primarily through vehicle performance, tolerability, application experience, packaging, and regulatory execution rather than active-ingredient exclusivity. The strongest commercial opportunities are differentiated emollient creams, low-irritancy preservative systems, enhanced barrier-repair vehicles, metered packaging, and specialty formulations for localized inflammatory dermatoses.

What is the regulatory and commercial status of clobetasol propionate emollient products?

Clobetasol propionate is a super-high-potency topical corticosteroid used for short-term treatment of corticosteroid-responsive dermatoses, including plaque psoriasis and eczema-related inflammatory conditions. The common strength is 0.05%.

The active ingredient is an established small molecule. Original product, formulation, and regulatory exclusivity barriers have largely expired. Commercial protection therefore depends on:

• Formulation differentiation
• Device or packaging claims
• New delivery technology
• Combination products
• New indications or dosing regimens
• Manufacturing know-how
• Brand recognition and distribution

FDA labeling generally limits clobetasol propionate treatment to short courses. For many cream, ointment, and solution products, labeling limits treatment to two consecutive weeks and total weekly use to 50 grams because of the risk of hypothalamic-pituitary-adrenal-axis suppression and other corticosteroid adverse effects.[1]

Key product and market attributes

Attribute	Commercial implication
Active ingredient	Low-cost, widely available generic corticosteroid
Typical strength	Clobetasol propionate 0.05%
Potency	Super-high potency
Main dosage forms	Cream, emollient cream, ointment, gel, lotion, solution, foam, shampoo, spray
Treatment duration	Usually short-term
Primary users	Dermatologists, primary-care prescribers, patients with inflammatory dermatoses
Main differentiation lever	Vehicle and delivery performance
Biosimilar exposure	None; clobetasol propionate is a small molecule
Generic exposure	High
Prescription status	Prescription drug in the United States
Principal risk	Excessive systemic or local corticosteroid exposure

What excipients are used in clobetasol propionate emollient cream?

A reference-style clobetasol propionate emollient cream uses a mixed oil-water vehicle designed to improve skin feel and hydration while maintaining delivery of a potent corticosteroid. Public labeling for Temovate E-type emollient cream identifies excipients including cetostearyl alcohol, cetyl alcohol, chlorocresol, citric acid, glycerin, glyceryl stearate, isopropyl myristate, paraffin, polyethylene glycol 100 stearate, purified water, sodium citrate, and white soft paraffin.[2]

Excipient functions

Excipient class	Typical examples	Formulation function
Emollient hydrocarbons	Liquid paraffin, white soft paraffin	Occlusion, barrier support, reduction of transepidermal water loss
Fatty alcohols	Cetyl alcohol, cetostearyl alcohol	Consistency, emollience, co-emulsification
Ester emollients	Isopropyl myristate	Spreadability, reduced greasiness, skin feel
Emulsifiers	Glyceryl stearate, PEG 100 stearate	Oil-in-water emulsion stability
Humectants	Glycerin	Hydration and moisturization
Preservatives	Chlorocresol or alternative systems	Microbiological protection
Buffers	Citric acid, sodium citrate	pH control and stability
Aqueous phase	Purified water	Continuous phase and processing medium

The formulation target is a compromise. More occlusion can improve hydration and residence time, but may increase greasiness, follicular occlusion, patient noncompliance, and the possibility of enhanced corticosteroid absorption. More volatile or lightweight excipients can improve sensory acceptance but may reduce substantivity and moisturization.

Which excipient strategies can differentiate clobetasol propionate products?

The most commercially credible strategy is a controlled shift from a conventional emollient cream toward a vehicle with measurable advantages in tolerability, application, stability, or adherence.

1. Low-grease emollient systems

Patients often avoid highly occlusive corticosteroid creams during daytime use. A low-grease system can use a balanced combination of:

• Lightweight esters
• Medium-chain triglycerides
• Branched hydrocarbons
• Volatile silicones, where permitted and justified
• Reduced levels of heavy petrolatum
• Structured emulsifier systems

The development objective is not maximum occlusion. It is adequate hydration and drug delivery with faster rub-in, lower residue, and improved cosmetic acceptance.

Potential commercial claims include:

• Non-greasy feel
• Rapid absorption
• Easy spreadability
• Suitable for daytime use
• Reduced transfer to clothing

Claims must be supported by product testing and cannot imply superior clinical efficacy without appropriate evidence.

2. Barrier-repair emollient vehicles

A barrier-focused product could combine clobetasol propionate with excipients associated with epidermal hydration and barrier support, such as glycerin, fatty alcohols, ceramide-compatible lipid systems, cholesterol, or selected non-irritating lipids.

This approach has commercial value in eczema and chronic xerotic dermatoses, where inflammation and barrier dysfunction coexist. The main technical challenge is maintaining chemical and physical stability while avoiding a vehicle that changes corticosteroid permeation beyond the intended profile.

A barrier-repair positioning is more defensible when the product is designed for short-term anti-inflammatory treatment followed by continued use of a nonsteroidal moisturizer. A combination product containing clobetasol and a second active barrier-repair ingredient would create a higher regulatory and clinical burden.

3. Preservative reduction or preservative-free design

Preservatives can cause irritation or allergic contact dermatitis in susceptible patients. A preservative-reduced or preservative-free emollient cream could target:

• Patients with compromised skin barriers
• Patients with known preservative sensitivity
• Pediatric or recurrent-use populations, subject to labeling restrictions
• Dermatology practices seeking simpler excipient profiles

A preservative-free multidose package creates microbiological risk. The preferred commercial architecture may be an airless pump, unit-dose sachet, or other package that reduces repeated environmental exposure.

The package is part of the formulation strategy. Removing a preservative without redesigning the container, filling process, microbial controls, and in-use stability program is not a viable product plan.

4. pH and irritation optimization

A mildly acidic emulsion may support skin compatibility and preservative performance, but pH must be balanced against:

• Clobetasol propionate chemical stability
• Emulsion stability
• Preservative efficacy
• Skin irritation
• Packaging compatibility

A development program should measure pH drift, assay, degradation products, droplet-size distribution, viscosity, preservative effectiveness, and microbial limits over the proposed shelf life.

5. Sensory engineering

Sensory properties are commercially important for a short-course product because patients may discontinue treatment when the vehicle is sticky, slow to dry, shiny, or difficult to remove.

Useful screening endpoints include:

• Rub-in time
• Residual tack
• Greasiness
• Whiteness after application
• Skin softness
• Transfer to fabric
• Wash-off behavior
• Odor
• Post-application irritation

Instrumental rheology and tribology can support claims, but consumer or clinician preference data are often more useful for brand positioning.

What formulation patents could protect a clobetasol propionate emollient product?

The active ingredient itself provides limited opportunity for new composition-of-matter protection. A patent strategy would focus on the formulation, delivery system, manufacturing process, or clinical use.

Potential patentable subject matter

IP category	Possible claim focus	Commercial value
Emulsion composition	Defined oil phase, emulsifier ratio, humectant, pH, viscosity	Moderate if difficult to design around
Low-irritancy system	Specific preservative-free or reduced-preservative vehicle	Moderate
Barrier-repair vehicle	Defined lipid combination with clobetasol	Moderate to high if clinically differentiated
Particle or droplet engineering	Controlled droplet size or drug distribution	Moderate
Packaging	Airless pump or metered delivery system	Moderate
Manufacturing process	Controlled homogenization, cooling, or filling process	Moderate
Method of use	Shortened treatment, maintenance, or specific anatomic site	Potentially high, but clinical evidence is required
Combination therapy	Clobetasol with another active ingredient	High regulatory and litigation burden
Device-assisted delivery	Applicator, spray, or film-forming system	Potentially high

The strongest formulation patent is usually one that combines a narrow composition with a measurable performance result, such as improved stability, lower irritation, controlled delivery, or equivalent efficacy with reduced exposure. Broad claims covering ordinary petrolatum, glycerin, fatty alcohols, and standard emulsifiers are vulnerable to invalidity and design-around attacks.

When does clobetasol propionate emollient lose exclusivity?

Clobetasol propionate emollient products have no meaningful remaining new-molecular-entity exclusivity in the United States. The market is subject to generic competition, and the commercial value of a product depends on its specific NDA, ANDA, formulation, and patent history.

Exclusivity timeline

Milestone	Status
Active ingredient approval	Historical; long expired
Original branded topical exclusivity	Expired
Generic competition	Established
Biosimilar pathway	Not applicable
Current differentiation	Formulation, packaging, brand, channel, and clinical positioning

The FDA Orange Book remains the controlling source for current listed patents and exclusivity associated with a particular prescription product.[3] Old topical corticosteroid products may have no active Orange Book patents, while a later product with a novel vehicle, spray system, foam, or combination may have separate listings.

What is the Orange Book and Paragraph IV risk for clobetasol emollient products?

Generic applicants can challenge listed patents through an ANDA Paragraph IV certification. For a conventional clobetasol propionate emollient cream, the main risks are usually formulation and regulatory rather than active-ingredient patent risk.

Paragraph IV exposure

A generic applicant may challenge:

• A formulation patent
• A delivery-system patent
• A method-of-use patent
• A package or device patent, where listed and legally eligible
• A patent covering a specific vehicle or combination

A sponsor with an innovative emollient product should expect the following defenses from generic applicants:

1. The patent does not cover the proposed product.
2. The claims are anticipated by earlier topical formulations.
3. The claims would have been obvious to a formulation scientist.
4. The patent lacks adequate written description or enablement.
5. The proposed generic does not infringe.
6. The method-of-use labeling can omit the patented use.

The 30-month stay available after a timely patent infringement action can delay ANDA approval, but it does not guarantee eventual market exclusivity. Product-specific Orange Book analysis is required for litigation forecasting.[4]

What FDA pathway applies to a new clobetasol propionate emollient?

A conventional generic cream is generally developed through the ANDA pathway. A materially different vehicle, new indication, new dosing concept, or combination may require a 505(b)(2) application.

ANDA pathway

An ANDA sponsor typically must demonstrate:

• Pharmaceutical equivalence
• Bioequivalence or applicable topical-equivalence evidence
• Appropriate active-ingredient and inactive-ingredient controls
• Comparable strength and dosage form
• Manufacturing quality
• Stability
• Microbiological quality
• Labeling consistent with the reference product

For topical semisolid products, FDA review can involve comparative physicochemical characterization, product quality testing, and in vitro release testing. FDA's SUPAC-SS guidance addresses postapproval changes for nonsterile semisolid dosage forms, including creams, gels, lotions, and ointments.[5]

505(b)(2) pathway

A 505(b)(2) product could support a differentiated vehicle or delivery system where the sponsor relies partly on existing FDA findings for clobetasol propionate but generates new data for:

• A new indication
• A materially different dosage form
• A new delivery device
• A new dosing regimen
• A novel combination
• A clinically meaningful safety or tolerability proposition

The 505(b)(2) route is commercially attractive only when the formulation provides a defensible benefit. A cosmetic improvement alone may not justify the added clinical and regulatory expense.

What manufacturing and intellectual-property barriers affect commercial entry?

The active ingredient is not the primary barrier. The more difficult technical problems are emulsion reproducibility, drug distribution, preservative performance, and scale-up.

Key manufacturing risks

• Nonuniform clobetasol distribution at low drug loading
• Crystal formation or polymorphic changes
• Droplet-size changes during scale-up
• Viscosity drift
• Phase separation
• Preservative failure
• Air entrapment
• Inconsistent filling weight
• Pump dose variability
• Container interaction
• Drug adsorption to packaging
• Inadequate in-use stability

A commercial process should establish controls for temperature, shear, order of addition, homogenization, cooling rate, bulk hold time, and filling conditions. Process know-how can create a practical barrier even when composition claims are narrow.

What are the best commercial opportunities in clobetasol emollient?

Premium generic cream

A branded or authorized-generic product can compete on:

• Better cosmetic acceptance
• Lower residue
• Improved packaging
• Preservative reduction
• Consistent dose delivery
• Dermatology-focused distribution

The product must justify any price premium against numerous low-cost generic creams and ointments.

Dermatology channel product

A premium emollient cream may gain traction through dermatology practices if it addresses adherence and tolerability. Physician adoption is more likely when supported by:

• Comparative vehicle data
• Patient preference studies
• Consistent supply
• Clear usage instructions
• Commercial rebates or specialty distribution

Private-label and contract manufacturing

Clobetasol emollient cream is suitable for private-label development because the formulation platform can be adapted for different channels. Opportunities include pharmacy chains, teledermatology platforms, regional distributors, and international partners.

The principal constraints are prescription status, country-specific labeling, potency classification, and local requirements for topical-equivalence evidence.

International geographic expansion

Geographic opportunities exist in markets with:

• Established dermatology prescribing
• High generic utilization
• Demand for premium topical vehicles
• Local manufacturing or licensing incentives
• Limited availability of cosmetically acceptable super-potent corticosteroids

Patent freedom-to-operate is jurisdiction-specific. A formulation patent filed in the United States may not affect Europe, Canada, Japan, Latin America, or emerging markets. Regulatory classification and corticosteroid scheduling can differ materially by country.

How does clobetasol emollient compare with other clobetasol dosage forms?

Dosage form	Main advantage	Main limitation	Commercial position
Emollient cream	Balance of hydration, spreadability, and patient acceptance	Emulsion stability and preservative complexity	Broadest differentiation opportunity
Ointment	Strong occlusion and high substantivity	Greasy, poor daytime acceptance	Low-cost, high-occlusion segment
Foam	Fast application and good scalp/body use	Higher packaging and manufacturing cost	Premium branded opportunity
Shampoo	Scalp-specific delivery	Short contact time, niche use	Specialty segment
Lotion	Lightweight application	Lower occlusion	Large-surface-area use
Solution	Low residue and easy scalp application	Limited barrier support	Scalp and hair-bearing areas
Spray	Convenient application, reduced hand contact	Device and dose-uniformity risk	Premium convenience segment
Gel	Quick drying and low grease	Can sting compromised skin	Niche cosmetic-positioning segment

The emollient cream occupies the middle of the market. It has more barrier support than a solution or gel and better cosmetic acceptability than a heavy ointment. That positioning supports incremental innovation without requiring a new active ingredient.

What generic launch scenarios exist?

Scenario 1: Conventional low-cost generic

This is the most likely competitive baseline. The generic uses a conventional cream or emollient vehicle and competes primarily on price and pharmacy access.

Scenario 2: Formulation-led premium generic

A sponsor launches a low-grease, preservative-reduced, or airless-pump product. Success depends on demonstrable adherence or tolerability benefits and effective dermatology-channel promotion.

Scenario 3: 505(b)(2) differentiated product

A sponsor develops a novel delivery system or clinical use. This creates a larger evidence burden but may support more durable pricing and formulation patents.

Scenario 4: Authorized generic or licensing deal

A brand owner or formulation developer licenses manufacturing, distribution, or an authorized-generic version. The economic rationale is strongest where the partner has unused manufacturing capacity or access to a high-value dermatology channel.

No specific current licensing transaction should be assumed from the existence of the dosage form. Each proposed deal requires review of ownership, manufacturing rights, territory, regulatory responsibility, and patent obligations.

How strong is the patent estate for clobetasol propionate emollient?

The underlying active-ingredient patent estate is weak because clobetasol propionate is an old generic corticosteroid. A new product can have a stronger estate only if its claims are tied to a genuine formulation or delivery advance.

Patent-strength assessment

Patent layer	Expected strength
Clobetasol propionate composition of matter	Very weak or expired
Conventional emollient cream	Weak unless narrowly defined and technically unexpected
Specific excipient ratio	Moderate if supported by data and difficult to design around
Preservative-free package system	Moderate
Novel device or metered delivery	Moderate to strong
Clinical method-of-use claim	Variable; depends on evidence and claim scope
Manufacturing process	Moderate practical value, often difficult to enforce
Trade secrets	Potentially valuable for scale-up and stability

The most defensible strategy is a layered estate combining formulation claims, package claims, process know-how, trademarks, and clinical data. A single broad cream-composition patent is unlikely to provide durable protection.

Key Takeaways

• Clobetasol propionate emollient is a mature, genericized small-molecule product with no biosimilar risk.
• Excipients are the primary commercial differentiation tool.
• The most attractive formulation concepts are low-grease emulsions, barrier-supportive vehicles, preservative-reduced systems, and metered or airless packaging.
• Conventional excipient combinations are difficult to protect broadly and require narrow, data-supported claims.
• Generic competition is established, so premium pricing requires measurable improvements in tolerability, application, adherence, or dose consistency.
• ANDA development is appropriate for a conventional generic; a materially novel vehicle or use may support a 505(b)(2) strategy.
• Manufacturing control of drug distribution, emulsion stability, preservative efficacy, and packaging performance is a more important barrier than the active ingredient.
• The best licensing targets are formulation platforms, dermatology distribution partners, contract manufacturers, and regional rights holders.

FAQs About Clobetasol Propionate Emollient Excipient Strategy

Can ceramides be added to clobetasol propionate emollient cream?

Yes, but the combination requires compatibility, stability, preservative, permeation, and regulatory evaluation. Ceramides can support a barrier-repair positioning but may complicate emulsion structure and manufacturing.

Is a preservative-free clobetasol cream commercially attractive?

It can be attractive for patients with sensitive or damaged skin, but the package must control microbial contamination. Airless pumps and unit-dose formats may be more suitable than conventional jars.

Can a new excipient create patent protection?

A new excipient alone rarely creates strong protection. Patent value is greater when the excipient is part of a defined composition that produces unexpected stability, tolerability, delivery, or adherence results.

Does clobetasol emollient cream have biosimilar competition?

No. Clobetasol propionate is a small-molecule active ingredient. Competitive entry occurs through generic drug pathways rather than biosimilar pathways.

Which dosage form has the highest commercial differentiation potential?

Foam, spray, and metered delivery systems generally provide more differentiation than conventional cream. Emollient cream remains attractive because it combines broad prescriber familiarity with opportunities for sensory and barrier-repair improvement.

References

1. U.S. Food and Drug Administration. (2023). Clobetasol propionate cream, 0.05% prescribing information. FDA/DailyMed.

2. U.S. National Library of Medicine. (n.d.). Temovate E and clobetasol propionate emollient cream, 0.05%: Drug label. DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Hatch-Waxman amendments and ANDA patent certifications. FDA.

5. U.S. Food and Drug Administration. (1997). SUPAC-SS: Nonsterile semisolid dosage forms, scale-up and postapproval changes. FDA.